HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderlini, P. Articles by Körbling, M. Search for Related Content PubMed PubMed Citation Articles by Anderlini, P. Articles by Körbling, M.

The Use of Mobilized Peripheral Blood Stem Cells from Normal Donors for Allografting

The University of Texas M.D. Anderson Cancer Center, Department of Hematology, Section of Blood and Marrow Transplantation, Houston, Texas, USA

Key Words. Allogenic peripheral blood stem cell transplantation • Stem cell mobilization • Recombinant human granulocyte colony-stimulating factor (rHuG-CSF) • Graft-versus-host disease • Graft-versus-leukemia

Dr. Martin Körbling, University of Texas M.D. Anderson Cancer Center, Department of Hematology, Box 24, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Peripheral blood stem cells (PBSCs) are gaining increasing acceptance as an alternative to bone-marrow (BM)-derived stem cells for allografting. Although scarce under steady-state conditions, CD34⁺ progenitor cells can be effectively mobilized into the peripheral blood (PB) in the vast majority of normal donors with a brief (3-4 days) course of recombinant human (rHu)G-CSF. Those cytokine-peripheralized progenitor cells and, among them, pluripotent stem cells, are collected by apheresis in sufficient amounts to achieve complete and permanent alloengraftment after myeloablative treatment in patients with primarily malignant hematologic disorders. The short-term tolerability profile of PBSC mobilization and apheresis in normal donors appears to be acceptable, although continued monitoring is necessary to ensure long-term safety. When compared with BM progenitor cells, mobilized PBSCs seem to exhibit a more primitive phenotype and a different clonogenic potential. The impact of factors affecting the efficiency of PBSC mobilization, such as rHuG-CSF dose, duration of cytokine treatment, and, to a lesser extent, donor age is now being recognized. Potential ways to optimize and possibly "engineer" PBSC collection, such as the use of cytokine/chemokine combinations (e.g., thrombopoietin, stem cell factor, etc.) and monoclonal antibodies directed against integrin receptors on CD34⁺ progenitor cells, are now being explored as well. In the clinical setting, engraftment after PBSC allografting is rapid and probably faster than after BM allografting. PBSC allografting seems to be associated with an incidence and severity of acute graft-versus-host disease (GVHD) comparable to the ones observed after BM allografting, although the incidence of chronic GVHD after allogeneic PBSC transplantation is still controversial. The infusion of a larger number of lymphoid cells appears to translate into a more rapid immunologic recovery and may lead to an enhanced graft-versus-leukemia effect. The collection of large numbers of mobilized PBSCs should provide ample opportunities for graft engineering and gene therapy. PBSCs may eventually replace, at least in part, BM as the preferred source of stem cells for both auto- and allotransplantation.

This article has been cited by other articles:

				P. Schwarzenberger, W. Huang, P. Oliver, P. Byrne, V. La Russa, Z. Zhang, and J. K. Kolls IL-17 Mobilizes Peripheral Blood Stem Cells with Short- and Long-Term Repopulating Ability in Mice J. Immunol., August 15, 2001; 167(4): 2081 - 2086. [Abstract] [Full Text] [PDF]

				N. A. Marshall, J. G. Howe, R. Formica, D. Krause, J. E. Wagner, N. Berliner, J. Crouch, I. Pilip, D. Cooper, B. R. Blazar, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation Blood, October 15, 2000; 96(8): 2814 - 2821. [Abstract] [Full Text] [PDF]

				F. Arpaci, S. Komurcu, B. Ozturk, A. Ozet, C. Kinalp, A. Sengul, M. Beyzadeoglu, Y. Pak, and A. Yalcin A Successful and Simplified Filgrastim Primed Single Apheresis Method Without Large Volume Apheresis for Peripheral Blood Stem Cell Collection Jpn. J. Clin. Oncol., March 1, 2000; 30(3): 153 - 158. [Abstract] [Full Text] [PDF]

				M. Engelhardt, H. Bertz, M. Afting, C. F. Waller, and J. Finke High- Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34+ Immunoselection J. Clin. Oncol., July 1, 1999; 17(7): 2160 - 2160. [Abstract] [Full Text] [PDF]

				J. C.M. van der Loo, H. Hanenberg, R. J. Cooper, F.-Y. Luo, E. N. Lazaridis, and D. A. Williams Nonobese Diabetic/Severe Combined Immunodeficiency (NOD/SCID) Mouse as a Model System to Study the Engraftment and Mobilization of Human Peripheral Blood Stem Cells Blood, October 1, 1998; 92(7): 2556 - 2570. [Abstract] [Full Text] [PDF]

				M. Z. Ratajczak, J. Ratajczak, B. Machalinski, R. Mick, and A. M. Gewirtz In Vitro and In Vivo Evidence That Ex Vivo Cytokine Priming of Donor Marrow Cells May Ameliorate Posttransplant Thrombocytopenia Blood, January 1, 1998; 91(1): 353 - 359. [Abstract] [Full Text] [PDF]